Early Outcomes of Prostatic Artery Embolization using n-Butyl Cyanoacrylate Liquid Embolic Agent: A Safety and Feasibility Study

David Bamshad; Jay Sanghvi; Naveen Galla; Adam Geffner; Kartikeya Menon; Vivian Bishay; Dan Shilo; Kirema Garcia-Reyes; Robert Lookstein; Ardeshir Rastinehad; Aaron Fischman

doi:10.1016/j.jvir.2024.07.018

Early Outcomes of Prostatic Artery Embolization using n-Butyl Cyanoacrylate Liquid Embolic Agent: A Safety and Feasibility Study

J Vasc Interv Radiol. 2024 Jul 27:S1051-0443(24)00492-5. doi: 10.1016/j.jvir.2024.07.018. Online ahead of print.

Authors

Affiliations

¹ Department of Diagnostic, Molecular and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: [email protected].
² Department of Medical Education, Icahn School of Medicine at Mount Sinai, New York, New York.
³ Department of Diagnostic, Molecular and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, New York.
⁴ The Smith Institute for Urology at Lenox Hill, Northwell Health, New York, New York.

PMID: 39074551
DOI: 10.1016/j.jvir.2024.07.018

Abstract

This retrospective study evaluated the feasibility, safety, and short-term effectiveness of prostatic artery embolization (PAE) using n-butyl cyanoacrylate (nBCA) glue embolization in 244 patients from June 2022 through May 2024. Technical success, defined as bilateral glue embolization, was achieved in 95% of cases. The median fluoroscopy time was 22.2 minutes (interquartile range [IQR], 17.1-30.0 minutes), and the median air kerma was 753 mGy (IQR, 417-1,559 mGy). Compared with baseline, statistically significant improvements were observed at 7.1 weeks for the International Prostate Symptom Score (9.5 [SD ± 6.0] vs 20.5 [SD ± 6.7]; P < .01), quality of life (1.8 [SD ± 1.5] vs 4.0 [SD ± 1.1]; P < .01), Q_max (10.4 mL/s [SD ± 6.3] vs 6.1 mL/s [SD ± 2.5]; P < .01), and prostate grand volume at 6 months (113.3 mL [SD ± 69.3] vs 156.6 mL [SD ± 104.6]; P < .01). These results demonstrate the use of nBCA for PAE as a technically feasible and safe option with excellent short-term outcomes.